Direct-to-Consumer Surgery: Non-invasive liposuction for the masses

Not so very long ago, reimbursement was king in the world of medical devices. But the overnight success of injectible anti-wrinkle drug Botox signalled a change in the market. Now device companies developing liposuction alternatives hope to repeat that success, perhaps most importantly, in building their businesses outside of traditional reimbursement circles with a largely consumer-driven or self-pay market with new devices for cosmetic surgery applications.

Not so very long ago, reimbursement was king in the world of medical devices. Without reimbursement, there was no market, particularly for devices that had any degree of invasiveness to them. For that reason, if companies with surgical or even minimally invasive devices dreamed of one day selling to the virtually unlimited consumer market, they took the high road to the marketplace, by targeting a dire, and reimbursable, medical need first. Thus, Allergan Inc. , which had a multi-focal lens that could help the middle aged see both near and far without reading glasses, positioned its implantable device for the cataract market. Medtronic Inc. , looking into the market for obesity devices, got its electrical stimulation device approved for gastroparesis, an uncommon but horrendous disorder that causes frequent vomiting. (See "Obesity: Supersized Medical Device Market Also see "Obesity: Super-Sized Medical Device Market " - Medtech Insight, 1 March, 2003.) And injectable anti-wrinkle drug Botox (botulinum toxin) first entered the market as a therapy for a rare facial twitching disorder. But things are changing, and it was perhaps the overnight success of Botox that first signaled this shift.

Botox has boomed since its introduction in 2000; there were 1.6 million Botox injections in 2002, up 4% over the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

Warning Letters – June 2025

The US FDA posted eight device-related warning letters in June, touching on industry sectors from urinalysis test strips to ophthalmic devices.

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By 

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.

Burden Is Too Heavy For Medtechs To Go It Alone On Complex Medtech AI Projects

 

Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.

More from Medtech Insight

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By 

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

European MedTech Keeps Calm Despite US Threats Of 30% Tariffs

 

MedTech Europe wants the EU to continue its commitment to reach a negotiated tariff solution with the US and measured restraint amid escalating trade tensions.

Medtech Will Benefit From Boost To EU’s Quantum Technology Initiative

 

The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”